Skip to content

(LARS) Score Validation of Turkish Language

Validation of the Turkish Translation of the Low Anterior Resection Syndrome (LARS) Score

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05289531
Enrollment
222
Registered
2022-03-21
Start date
2016-02-01
Completion date
2020-02-28
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LARS - Low Anterior Resection Syndrome

Keywords

Turkish LARS

Brief summary

Long-term bowel dysfunction after resection for rectal cancer, known as low anterior resection syndrome (LARS), is observed in many patients. The LARS score was developed to measure this syndrome and its impact on quality of life in Danish patients. Recently, English and many other language versions have been validated. The aim of this study was to validate the Turkish translation of the LARS score in Turkish patients who have undergone treatment for rectal cancer.

Detailed description

A total of 326 patients were reviewed and contacted for the study, and 222 (68%) were eligible for the analyses. The association between the LARS score and quality of life and the test-retest reliability were studied. The intraclass correlation coefficient (ICC) was calculated to understand the degree of reliability.

Interventions

PROCEDURERectal Resection Patients

Patients who have had low anterior resection of rectum was categorized for their quality of life related to surgery

Sponsors

Aarhus University Hospital
CollaboratorOTHER
Dokuz Eylul University
CollaboratorOTHER
Lokman Hekim University
CollaboratorOTHER_GOV
Ankara University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

The inclusion criteria were * rectal adenocarcinoma within 15 cm from the anal verge * LAR with either PME or TME. * Bowel continuity restored for at least 18 months when invited for the study.

Design outcomes

Primary

MeasureTime frameDescription
Validity of LARS ScoreFrom Feb 2016 to Feb 2020The translated questionaire was validated on Turkish speaking patients

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026